Breaking News Instant updates and real-time market news.

XBIT

XBiotech

$9.29

-0.47 (-4.82%)

08:26
10/23/19
10/23
08:26
10/23/19
08:26

XBiotech announces first patient enrolled in study evaluating bermekimab

XBiotech announced that the first patient was enrolled in its randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating bermekimab in patients with moderate to severe Hidradenitis Suppurativa. The multi-center, international study will enroll approximately 150 patients into three arms: two bermekimab dosing regimens versus a placebo arm over sixteen weeks of therapy. The study is chaired by renowned investigative dermatologist Alice Gottlieb, MD, PhD, Medical Director of dermatology at the Mount Sinai Beth Israel Campus and Clinical Professor at the Icahn School of Medicine at Mount Sinai. The study's primary endpoint is the percentage of subjects achieving Hidradenitis Suppurativa Clinical Response at week 12. Multiple secondary efficacy endpoints will be assessed after 12 and 16 weeks of therapy, including: Numerical Rating Scale for pain and itch; Modified Sartorius Score; Dermatology Life Quality Index; Hospital Anxiety and Depression Scale; and Patient Global Impression of Change and Severity. Bermekimab has demonstrated its safety and efficacy treating HS in two previous clinical studies. A recent open label study demonstrated that weekly bermekimab is an effective therapy, as measured by improvement in disease according to HiSCR, the key measure of disease in HS. In the study, 61% of patients with no prior biological therapy achieved positive HiSCR at 12 weeks1, and 63% of patients who had failed previous biological therapy achieved a positive HiSCR at 12 weeks. Another unrivaled finding in the study was a significant treatment-related reduction of pain in HS patients. Reducing pain is widely recognized among experts as a key objective for HS treatment, but this symptom has been largely unaddressed by available drugs. Pain was assessed with a patient questionnaire using a numerical rating scale from 0 to 10. A 30% and greater than or equal to1-unit reduction in pain score is considered a clinically important relief from pain, and no approved monotherapy for HS has elicited a clinically significant effect on pain. Remarkably, a substantial majority of patients treated with weekly bermekimab achieved this endpoint: 67% and 72% at week 12 who had prior or no prior anti-TNF therapy, respectively. An earlier double-blind, placebo controlled, randomized study also evaluated bermekimab in the treatment of HS. The study met its primary endpoint, demonstrating significant improvement of HiSCR in patients treated with bermekimab compared to control after 12 weeks of therapy.

  • 28

    Oct

XBIT XBiotech
$9.29

-0.47 (-4.82%)

06/14/19
PIPR
06/14/19
INITIATION
Target $13
PIPR
Overweight
XBiotech initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro started XBiotech with an Overweight rating and $13 price target. Clinical activity for the company's lead asset bermekimab in two inflammatory skin diseases - hidradenitis suppurativa and atopic dermatitis - has been "very encouraging," Catanzaro tells investors in a research note. He believes these early data compare favorably to standard of care biologics Humira and Dupixent in each setting, respectively. The analyst expects XBiotech shares to appreciate as it advances bermekimab in both indications.

TODAY'S FREE FLY STORIES

12:05
11/13/19
11/13
12:05
11/13/19
12:05
General news
Powell didn't fully answer why analysts have low rates even as government spending increases »

Powell didn't fully…

DIS

Disney

$137.19

-1.37 (-0.99%)

12:04
11/13/19
11/13
12:04
11/13/19
12:04
Hot Stocks
Disney turns positive after announcing 10M streaming sign-ups »

The stock is up 15c to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$179.30

-0.49 (-0.27%)

, MA

MasterCard

$278.23

1.12 (0.40%)

12:04
11/13/19
11/13
12:04
11/13/19
12:04
Periodicals
FTC probing Visa, MasterCard over debit card transactions, Bloomberg reports »

Visa (V) and MasterCard…

V

Visa

$179.30

-0.49 (-0.27%)

MA

MasterCard

$278.23

1.12 (0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

DIS

Disney

$137.23

-1.33 (-0.96%)

12:03
11/13/19
11/13
12:03
11/13/19
12:03
Hot Stocks
Breaking Hot Stocks news story on Disney »

Disney says streaming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENR

Energizer

$47.45

5.44 (12.95%)

12:00
11/13/19
11/13
12:00
11/13/19
12:00
Hot Stocks
Energizer rises 13.2% »

Energizer is up 13.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 21

    Nov

SPB

Spectrum Brands

$60.10

8.91 (17.41%)

12:00
11/13/19
11/13
12:00
11/13/19
12:00
Hot Stocks
Spectrum Brands rises 17.0% »

Spectrum Brands is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

LN

Line Corp.

$49.79

9.12 (22.42%)

12:00
11/13/19
11/13
12:00
11/13/19
12:00
Hot Stocks
Line Corp. rises 21.9% »

Line Corp. is up 21.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRX

Catalyst Pharmaceuticals

$4.40

-0.51 (-10.39%)

11:57
11/13/19
11/13
11:57
11/13/19
11:57
Recommendations
Catalyst Pharmaceuticals analyst commentary  »

Catalyst Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CTAS

Cintas

$249.50

-9.4 (-3.63%)

11:56
11/13/19
11/13
11:56
11/13/19
11:56
Recommendations
Cintas analyst commentary  »

Baird says Cintas short…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$193.14

-1.33 (-0.68%)

11:55
11/13/19
11/13
11:55
11/13/19
11:55
Periodicals
China-owned TikTok is challenging Facebook for advertisers, Adweek says »

Adweek's platforms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIF

Tiffany

$122.85

-1.25 (-1.01%)

11:50
11/13/19
11/13
11:50
11/13/19
11:50
Options
Put sale in Tiffanys opens 100 strike block in Feb »

Put sale in Tiffanys…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:50
11/13/19
11/13
11:50
11/13/19
11:50
General news
Powell on the next downturn: generally the Fed has cut 500 bps in recessions »

Powell on the next…

TCDA

Tricida

$37.50

-2.21 (-5.57%)

11:49
11/13/19
11/13
11:49
11/13/19
11:49
Conference/Events
Tricida participates in a conference call with JPMorgan »

SMid Biotech Analyst Fye…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

ADPT

Adaptive Biotechnologies

$26.60

-1.75 (-6.17%)

11:47
11/13/19
11/13
11:47
11/13/19
11:47
Recommendations
Adaptive Biotechnologies analyst commentary  »

Adaptive Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

KNSA

Kiniksa

$6.62

-0.1 (-1.49%)

11:40
11/13/19
11/13
11:40
11/13/19
11:40
Conference/Events
Kiniksa participates in a conference call with JMP Securities »

JMP Securities hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

11:40
11/13/19
11/13
11:40
11/13/19
11:40
General news
Powell on max employment: the economy can operate at a much lower level of unemployment »

Powell on max employment:…

AAPL

Apple

$264.01

2.12 (0.81%)

, SJM

J.M. Smucker

$105.50

0.36 (0.34%)

11:36
11/13/19
11/13
11:36
11/13/19
11:36
On The Fly
Apple initiation, J.M. Smucker downgrade among today's top analyst calls »

Check out today's top…

AAPL

Apple

$264.01

2.12 (0.81%)

SJM

J.M. Smucker

$105.50

0.36 (0.34%)

TTWO

Take-Two

$119.53

0.53 (0.45%)

MOS

Mosaic

$20.05

-0.89 (-4.25%)

FCX

Freeport McMoRan

$10.93

-0.12 (-1.09%)

AA

Alcoa

$21.64

-0.545 (-2.46%)

ALB

Albemarle

$65.09

-0.19 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 19

    Nov

  • 21

    Nov

  • 22

    Nov

  • 12

    Dec

LYV

Live Nation

$64.81

0.055 (0.08%)

11:35
11/13/19
11/13
11:35
11/13/19
11:35
Hot Stocks
Live Nation, Rakuten partner to offer new members rewards and ticket offers »

Rakuten and Live Nation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIP

TripAdvisor

$30.77

-0.93 (-2.93%)

11:35
11/13/19
11/13
11:35
11/13/19
11:35
Options
TripAdvisor put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Nov

  • 26

    Nov

V

Visa

$179.73

-0.06 (-0.03%)

, MA

MasterCard

$279.01

1.9 (0.69%)

11:33
11/13/19
11/13
11:33
11/13/19
11:33
Periodicals
FTC probing Visa, MasterCard over debit card transactions, Bloomberg reports »

The Federal Trade…

V

Visa

$179.73

-0.06 (-0.03%)

MA

MasterCard

$279.01

1.9 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

EXEL

Exelixis

$16.18

0.84 (5.48%)

11:25
11/13/19
11/13
11:25
11/13/19
11:25
Options
Exelixis call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESRX

Express Scripts

$0.00

(0.00%)

11:25
11/13/19
11/13
11:25
11/13/19
11:25
Conference/Events
Detroit Economic Club to hold a luncheon meeting »

Tim Wentworth, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

11:20
11/13/19
11/13
11:20
11/13/19
11:20
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
11/13/19
11/13
11:17
11/13/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
11/13/19
11/13
11:16
11/13/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.